L. Baldi, D. L. Hacker, M. Adam, and F. M. Wurm, Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives, Biotechnology Letters, vol.62, issue.2, pp.677-684, 2007.
DOI : 10.1007/s10529-006-9297-y

D. B. Baruah, R. N. Dash, M. R. Chaudhari, and S. S. Kadam, Plasminogen activators: A comparison, Vascular Pharmacology, vol.44, issue.1, pp.1-9, 2006.
DOI : 10.1016/j.vph.2005.09.003

T. Benavides-damm and F. M. Wurm, Generation of the stable cell line for the production of theraputic proteins using the Piggy Back transposon for transgene delivery, 2010.

K. Benchenane, J. P. Lopez-atalaya, M. Fernandez-monreal, O. Touzani, and D. Vivien, Equivocal roles of tissue-type plasminogen activator in stroke-induced injury, Trends in Neurosciences, vol.27, issue.3, pp.155-160, 2004.
DOI : 10.1016/j.tins.2003.12.011

P. J. Burck, D. H. Berg, M. W. Warrick, D. T. Berg, J. D. Walls et al., Characterization of a modified human tissue plasminogen activator comprising a kringle-2 and a protease domain, J. Biol. Chem, vol.265, pp.5170-5177, 1990.

F. Davami, S. Sardari, A. Majidzadeh, M. Hemayatkar, F. Barkhordari et al., A novel variant of t-PA resistant to plasminogen activator inhibitor-1; expression in CHO cells based on In Silico experiments, BMB Reports, vol.44, issue.1, pp.34-39, 2011.
DOI : 10.5483/BMBRep.2011.44.1.34
URL : https://hal.archives-ouvertes.fr/pasteur-00753196

F. Davami, S. Sardari, A. Majidzadeh, M. Hemayatkar, F. Barkhrdari et al., Expression of a Novel Chimeric Truncated t-PA in CHO Cells Based on in Silico Experiments, Journal of Biomedicine and Biotechnology, vol.137, issue.6, p.108159, 2010.
DOI : 10.1023/B:BILE.0000003992.09492.4b
URL : https://hal.archives-ouvertes.fr/pasteur-00821614

L. A. Erickson, M. H. Ginsberg, and D. J. Loskutoff, Detection and partial characterization of an inhibitor of plasminogen activator in human platelets., Journal of Clinical Investigation, vol.74, issue.4, pp.1465-1472, 1984.
DOI : 10.1172/JCI111559

M. Hemayatkar, F. Mahboudi, A. Majidzadeh, F. Davami, B. Vaziri et al., Increased expression of recombinant human tissue plasminogen activator in Leishmania tarentolae, Biotechnology Journal, vol.301, issue.11, pp.1198-1206, 2010.
DOI : 10.1002/biot.201000233
URL : https://hal.archives-ouvertes.fr/pasteur-00763505

C. Krishnamurti and B. M. Alving, Plasminogen Activator Inhibitor Type 1: Biochemistry and Evidence for Modulation of Fibrinolysis In Vivo, Seminars in Thrombosis and Hemostasis, vol.18, issue.01, pp.67-80, 1992.
DOI : 10.1055/s-2007-1002412

C. Krishnamurti, B. Keyt, P. Maglasang, and B. M. Alving, PAI-1-resistant t-PA: Low doses prevent fibrin deposition in rabbits with increased PAI-1 activity, Blood, vol.87, pp.14-19, 1996.

C. Krishnamurti, G. D. Young, C. F. Barr, C. A. Colleton, and B. M. Alving, Enhancement of tissue plasminogen activatorinduced fibrinolysis by activated protein C in endotoxin-treated rabbits, J. Lab. Clin. Med, vol.118, pp.523-530, 1991.

X. K. Li, H. R. Lijnen, L. Nelles, H. B. Van, J. M. Stassen et al., Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1, Blood, vol.79, pp.417-429, 1992.

A. Majidzadeh, V. Khalaj, D. Fatemeh, H. Mahdi, B. Farzaneh et al., Cloning and Expression of Functional Full-Length Human Tissue Plasminogen Activator in Pichia pastoris, Applied Biochemistry and Biotechnology, vol.15, issue.1???2, pp.2037-2048, 2010.
DOI : 10.1007/s12010-010-8979-z
URL : https://hal.archives-ouvertes.fr/pasteur-00763506

K. Mitsuyama, M. Sata, and S. , Interleukin-6 trans-signaling in inflammatory bowel disease, Cytokine & Growth Factor Reviews, vol.17, issue.6, pp.451-461, 2006.
DOI : 10.1016/j.cytogfr.2006.09.003

T. K. Nordt, C. Bode-novick, D. , and M. Rubinstein, Thrombolysis: Newer thrombolytic agents and their role in clinical medicine The tale of soluble receptors and binding proteins: From bench to bedside, Heart Cytokine Growth Factor Rev, vol.89, issue.18, pp.1358-1362, 2003.

N. F. Paoni, B. A. Keyt, C. J. Refino, A. M. Chow, H. V. Nguyen et al., A slow clearing, fibrinspecific , PAI-1 resistant variant of t-PA (T103N, KHRR 296- 299 AAAA), Thromb. Haemost, vol.70, pp.307-312, 1993.

D. Pennica, W. E. Holmes, W. J. Kohr, R. N. Harkins, G. A. Vehar et al., Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli, Nature, vol.2, issue.5897, pp.214-221, 1983.
DOI : 10.1038/301214a0

P. L. Pham, A. Kamen, and Y. Durocher, Large-Scale Transfection of Mammalian Cells for the Fast Production of Recombinant Protein, Molecular Biotechnology, vol.34, issue.2, pp.225-237, 2006.
DOI : 10.1385/MB:34:2:225

M. Ranby, N. Bergsdorf, G. Pohl, and P. Wallen, Isolation of two variants of native one-chain tissue plasminogen activator, FEBS Letters, vol.78, issue.2, pp.289-292, 1982.
DOI : 10.1016/0014-5793(82)80936-8

L. A. Rubin, C. C. Kurman, M. E. Fritz, W. E. Biddison, B. Boutin et al., Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro, J. Immunol, vol.135, pp.3172-3177, 1985.

R. V. Shohet, S. Spitzer, E. L. Madison, R. Bassel-duby, M. J. Gething et al., Inhibitor-resistant tissuetype plasminogen activator: An improved thrombolytic agent in vitro, Thromb. Haemost, vol.71, pp.124-128, 1994.

M. Soleimani, F. Mahboudi, N. Davoudi, A. Amanzadeh, M. Azizi et al., Expression of human tissue plasminogen activator in the trypanosomatid protozoan Leishmania tarentolae, Biotechnol. Appl. Biochem, vol.48, pp.55-61, 2007.

B. Sporri, M. Bickel, D. Dobbelaere, J. Machado-jr, and D. Lottaz, Soluble interleukin-1 receptor ??? reverse signaling in innate immunoregulation, Cytokine & Growth Factor Reviews, vol.12, issue.1, pp.27-32, 2001.
DOI : 10.1016/S1359-6101(00)00020-4

M. Stettler, X. Zhang, D. L. Hacker, J. M. De, and F. M. Wurm, Novel Orbital Shake Bioreactors for Transient Production of CHO Derived IgGs, Biotechnology Progress, vol.23, issue.6, pp.1340-1346, 2007.
DOI : 10.1021/bp070219i

T. Truelsen and R. Bonita, Advances in ischemic stroke epidemiology, Adv. Neurol, vol.92, pp.1-12, 2003.

J. Varley and J. Birch, Reactor design for large-scale suspension animal cell culture, Cytotechnology, vol.29, issue.3, pp.177-205, 1999.
DOI : 10.1023/A:1008008021481

O. F. Wagner, C. De-vries, C. Hohmann, H. Veerman, and H. Pannekoek, Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA., Journal of Clinical Investigation, vol.84, issue.2, 1989.
DOI : 10.1172/JCI114211

W. D. Weaver, The role of thrombolytic drugs in the management of myocardial infarction, Comparative clinical trials. Eur. Heart J, vol.17, pp.9-15, 1996.

F. Wurm and A. Bernard, Large-scale transient expression in mammalian cells for recombinant protein production, Current Opinion in Biotechnology, vol.10, issue.2, pp.156-159, 1999.
DOI : 10.1016/S0958-1669(99)80027-5

F. M. Wurm, Production of recombinant protein therapeutics in cultivated mammalian cells, Nature Biotechnology, vol.57, issue.11, pp.1393-1398, 2004.
DOI : 10.1038/nbt1021